Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.64 |
| ▸ | CNR2 | P34972 | 1/20 | 0.64 |
| ▸ | MAPK14 | Q16539 | 11/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.48 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1600270 | 1.00 | CNR1 (0.64) | CNR1CNR2MAPK14POLBDDR2 | |
| SCHEMBL4953382 | 0.87 | CNR1 (0.69) | CNR1CNR2MAPK14POLBKDM4E | |
| SCHEMBL2788543 | 0.87 | CNR1 (0.72) | CNR1CNR2MAPK14POLBDDR2 | |
| SCHEMBL1903515 | 0.81 | CNR1 (0.71) | CNR1CNR2MAPK14POLBKDM4E | |
| SCHEMBL6260918 | 0.81 | CNR1 (0.64) | CNR1CNR2MAPK14POLBDDR2 | |
| SCHEMBL1600223 | 0.80 | CNR1 (0.69) | CNR1CNR2MAPK14POLBKDM4E | |
| SCHEMBL12669723 | 0.80 | CNR1 (0.69) | CNR1CNR2MAPK14POLBKDM4E | |
| SCHEMBL1600220 | 0.78 | MAPK14 (0.57) | CNR1CNR2MAPK14MAPK13MAPK12 | |
| SCHEMBL1600219 | 0.78 | MAPK14 (0.57) | CNR1CNR2MAPK14MAPK13MAPK12 | |
| SCHEMBL1599885 | 0.78 | CNR1 (0.67) | CNR1CNR2MAPK14MAPK13MAPK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7919617-B2 | Cytokine inhibitors | iTherX Pharmaceuticals Inc. (US) | 2011-04-05 | — | — | US | disclosed |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | ITHERX PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-7749999-B2 | Alpha-ketoamides and derivatives thereof | ITHERX PHARMACEUTICALS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-20100093734-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093735-A1 | CYTOKINE INHIBITORS | ITHERX PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20050107399-A1 | Cytokine inhibitors | KEMIA, INC. | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107399-A1 | Cytokine inhibitors | TNF, IL1RN, IL1A | CNR1 2862/4885CNR2 2697/4885MAPK14 371/4885 |
| US-20100093734-A1 | CYTOKINE INHIBITORS | TNF, IL1RN, IL1A | CNR1 2862/4885CNR2 2697/4885MAPK14 371/4885 |
| US-20100273797-A1 | ALPHA-KETOAMIDES AND DERIVATIVES THEREOF | TNF, IL1A, IL1B | CNR1 375/4885CNR2 221/4885MAPK14 696/4885 |
| US-20100093735-A1 | CYTOKINE INHIBITORS | TNF, IL1RN, IL1A | CNR1 2862/4885CNR2 2697/4885MAPK14 371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.